164 related articles for article (PubMed ID: 2693187)
61. Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma.
Tay SK; Lai FM; Soh LT; Ho TH; Ang PT; Au E
Aust N Z J Obstet Gynaecol; 1992 Aug; 32(3):263-6. PubMed ID: 1280100
[TBL] [Abstract][Full Text] [Related]
62. [Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer].
Kinugasa M; Nishimura R; Hasegawa K; Okamura M; Kimura A; Ohtsu F; Takeuchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):188-94. PubMed ID: 1545171
[TBL] [Abstract][Full Text] [Related]
63. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy.
Scambia G; Panici PB; Baiocchi G; Amoroso M; Foti E; Greggi S; Mancuso S
Am J Obstet Gynecol; 1991 Feb; 164(2):631-6. PubMed ID: 1992715
[TBL] [Abstract][Full Text] [Related]
64. Carcinoembryonic antigen in patients treated with radiation therapy for invasive squamous cell carcinoma of the uterine cervix.
Donaldson E; Van Nagell JR; Wood EG; Pletsch Q; Goldenberg DM
AJR Am J Roentgenol; 1976 Nov; 127(5):829-31. PubMed ID: 987709
[TBL] [Abstract][Full Text] [Related]
65. A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.
Hirashima Y; Kobayashi H; Nishiguchi T; Miura K; Kanayama N
Anticancer Drugs; 2001 Aug; 12(7):627-30. PubMed ID: 11487720
[TBL] [Abstract][Full Text] [Related]
66. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
Coleman RE; Clarke JM; Slevin ML; Sweetenham J; Williams CJ; Blake P; Calman F; Wiltshaw E; Harper PG
Cancer Chemother Pharmacol; 1990; 27(1):52-4. PubMed ID: 2245492
[TBL] [Abstract][Full Text] [Related]
67. [Tumor cell death as reflected by the SCC-antigen level?].
Clasen BP; Péré P; Senekowitsch R; Menz E
Laryngorhinootologie; 1991 May; 70(5):250-4. PubMed ID: 2064701
[TBL] [Abstract][Full Text] [Related]
68. Cervical carcinoma: a comparison of four potential biochemical tumor markers.
Dodd JK; Henry RJ; Tyler JP; Houghton CR
Gynecol Oncol; 1989 Feb; 32(2):248-52. PubMed ID: 2910788
[TBL] [Abstract][Full Text] [Related]
69. [CEA and the clinical course in advanced carcinoma of the uterine cervix (author's transl)].
Braun P; Leyendecker G
Geburtshilfe Frauenheilkd; 1982 Jun; 42(6):462-7. PubMed ID: 6921128
[TBL] [Abstract][Full Text] [Related]
70. A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix.
Tebbutt N; Rischin D; Quinn M; Rome R; Millward MJ; Toner GC; Bishop JF
Aust N Z J Obstet Gynaecol; 1998 Feb; 38(1):87-90. PubMed ID: 9521400
[TBL] [Abstract][Full Text] [Related]
71. The potential for adjuvant therapy in early-stage cervical cancer.
Buxton EJ; Saunders N; Blackledge GR; Kelly K; Redman CW; Monaghan J; Paterson ME; Luesley DM
Cancer Chemother Pharmacol; 1990; 26 Suppl():S17-21. PubMed ID: 1693315
[TBL] [Abstract][Full Text] [Related]
72. Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors.
Guo HT; Bi XH; Lei T; Lv X; Yao G; Chen Y; Liu C
BMC Cancer; 2020 May; 20(1):441. PubMed ID: 32429859
[TBL] [Abstract][Full Text] [Related]
73. Uterine cervical extrarenal Wilms tumor managed without hysterectomy.
Iraniha S; Shen V; Kruppe CN; Downey EC
J Pediatr Hematol Oncol; 1999; 21(6):548-50. PubMed ID: 10598671
[TBL] [Abstract][Full Text] [Related]
74. A young woman with clear cell adenocarcinoma of the uterine cervix.
Seki H; Takada T; Sodemoto T; Hoshino H; Saitoh K; Uekusa T
Int J Clin Oncol; 2003 Dec; 8(6):399-404. PubMed ID: 14663645
[TBL] [Abstract][Full Text] [Related]
75. Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Boupaijit K; Suprasert P
Asian Pac J Cancer Prev; 2016; 17(3):1123-7. PubMed ID: 27039736
[TBL] [Abstract][Full Text] [Related]
76. [The relation between serum carcinoembryonic antigens (CEA) and response to chemotherapy in patients with advanced gastric cancer].
Saito D; Yoshida S; Hijikata A; Tajiri H; Yamaguchi H; Yoshimori M; Ohkura H; Okazaki N; Yoshida T; Yoshino M
Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):948-57. PubMed ID: 3480325
[No Abstract] [Full Text] [Related]
77. Effect of hyperthermia on proliferation and deviation of carcinoembryonic antigen and squamous cell carcinoma-related antigen of human esophageal carcinoma cells in culture.
Saito M; Sakamoto T; Tazawa K; Saito T; Yunoki T; Yokoyama Y; Yamagishi F; Shimizu T; Shinbo T; Karaki Y; Fujimaki M; Ochiai H; Saito T; Saito H
Hum Cell; 1996 Mar; 9(1):63-8. PubMed ID: 9183632
[TBL] [Abstract][Full Text] [Related]
78. [Management of postoperative cervical cancer patients classified according to the risk for recurrence, and the effect of surgical adjuvant chemotherapy on the high risk group].
Ueki M; Maeda T; Okamura S; Kanda T; Sano T; Sugimoto O
Nihon Gan Chiryo Gakkai Shi; 1983 Jun; 18(4):927-39. PubMed ID: 6619641
[No Abstract] [Full Text] [Related]
79. [Chemotherapy with mitomycin C, etoposide and cisplatin for adenocarcinoma of the uterine cervix].
Hara K; Iwasaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():201-4. PubMed ID: 15535234
[No Abstract] [Full Text] [Related]
80. [Tumor markers for cancer of the uterine cervix].
Numa F
Nihon Rinsho; 2004 Oct; 62 Suppl 10():109-12. PubMed ID: 15535216
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
